We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Troglitazone: Monotherapy Indication

Donna M. Lisi, PHARMD
Arch Intern Med. 1998;158(4):412. doi:.
Text Size: A A A
Published online


I would like to commend Dagogo-Jack and Santiago1 on their excellent article. There are just 2 points that warrant further clarification.

First, since this article went to press, troglitazone has been indicated for use alone and with sulfonylureas.2 When used with sulfonylureas, troglitazone, 200 mg once daily, should be initiated. The current dose of sulfonylureas should be continued upon initiation of troglitazone therapy. For patients whose symptoms are not responding adequately, the troglitazone dose should be increased at 2 to 4 weeks. The maximum recommended dose of troglitazone is 600 mg once daily. The dose of sulfonylureas may require lowering to optimize therapy. Troglitazone can be used as monotherapy in patients whose symptoms are not adequately controlled with diet alone. The starting dose for this patient population is 400 or 600 mg once daily. For patients whose symptoms are not responding to 400 mg once daily, the dose of troglitazone should be increased to 600 mg after 6 to 8 weeks. For patients whose symptoms are not responding adequately to 600 mg of troglitazone after 6 to 8 weeks, alternative therapeutic options should be pursued.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles